SG3 Management’s Standard BioTools LAB Stock Holding History

SG3 Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-115,000	Closed	-$520K	–	1179
2021 Q1	$520K	Buy	+115,000	New	+$632K	0.01%	766

Other funds holding LAB

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

SG3 Management's LAB Position: Q2 2021 in Review

SG3 Management sold out of Standard BioTools (LAB) in Q2 2021, closing a stake of 115,000 shares — an estimated $520K sold.

SG3 Management first reported a position in LAB in Q1 2021 and held it in 1 quarter. The position peaked at $520K in Q1 2021. 113 funds tracked by Wall St. Rank hold LAB as of Q2 2021.

SG3 Management reported no remaining Standard BioTools position as of Q2 2021 after selling out during the quarter.
SG3 Management sold 115,000 Standard BioTools shares in Q2 2021, an estimated $520K.
SG3 Management first reported a position in Standard BioTools in Q1 2021 and held it in 1 quarter.
SG3 Management's Standard BioTools position peaked at $520K in Q1 2021.
113 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2021.

Based on SG3 Management's 13F filing for Q2 2021, filed 16 Aug 2021.